Pappas Capital LLC

01/23/2007 | Press release | Archived content

FlowCardia, Inc. announces 510(k) clearance for its chronic total...

News | 01. 23. 2007

FlowCardia

FlowCardia, Inc., a medical device company developing endovascular devices for coronary and peripheral chronic total occlusion (CTO) recanalization, announcedFDA 510(k)clearance of the CROSSER(TM) 14 CTO Recanalization System. The CROSSER 14 is designed to facilitate the placement of guidewires beyond CTOs in coronary arteries.

Pappas Capital LLC published this content on January 23, 2007, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:13 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]